Skip to content

Study · Animal study (in vivo) · rat · 1997

6 results

Expression of vasoactive intestinal polypeptide receptor mRNA and secretory regulation by vasoactive intestinal polypeptide in rat submandibular and sublingual salivary glands.

Takai N, Yoshida Y, Shida T, Kondo E, Ueda Y, Kiyama H, Tohyama M

Archives of oral biology1 Mar 1997Cited by 3 (Europe PMC)

PMID9188989 (opens in a new tab)DOI10.1016/s0003-9969(97)00002-2 (opens in a new tab)PepBankPUB-09188989
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, VIP infused during chorda stimulation did not increase submandibular salivary flow.

    In plain wordsIn rats, VIP infusion during nerve stimulation did not raise saliva flow from the submandibular gland.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSubmandibular salivary flow with exogenous VIP
    Study

    ratn: not reported in source

    Rat submandibular and sublingual salivary glands
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    10(-12) - 10(-8) M · infusionAs given in this study (rat).

    Source sentences

    Summary
    Exogenous VIP 10(-12) - 10(-8) M) infusion at the same time as chorda stimulation caused no increase in salivary flow, but the salivary protein concentration was increased in a dose-dependent manner.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, VIP infused during chorda stimulation increased the salivary protein concentration of the submandibular gland in a dose-dependent manner.

    In plain wordsIn rats, VIP infusion during nerve stimulation raised the protein level in saliva from the submandibular gland, more at higher doses.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseSubmandibular salivary protein concentration with exogenous VIP
    Study

    ratn: not reported in source

    Rat submandibular and sublingual salivary glands
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    10(-12) - 10(-8) M · infusionAs given in this study (rat).

    Source sentences

    Summary
    Exogenous VIP 10(-12) - 10(-8) M) infusion at the same time as chorda stimulation caused no increase in salivary flow, but the salivary protein concentration was increased in a dose-dependent manner.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, VIP did not affect chorda-evoked salivary flow in the sublingual gland.

    In plain wordsIn rats, VIP did not change nerve-evoked saliva flow from the sublingual gland.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSublingual salivary flow with VIP
    Study

    ratn: not reported in source

    Rat submandibular and sublingual salivary glands
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the sublingual gland, neither VIP nor the VIP antagonist affected chorda-evoked salivary flow and protein concentration.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, VIP did not affect chorda-evoked salivary protein concentration in the sublingual gland.

    In plain wordsIn rats, VIP did not change the protein level in nerve-evoked saliva from the sublingual gland.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSublingual salivary protein concentration with VIP
    Study

    ratn: not reported in source

    Rat submandibular and sublingual salivary glands
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the sublingual gland, neither VIP nor the VIP antagonist affected chorda-evoked salivary flow and protein concentration.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 05AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rat salivary glands, VIP-containing nerve fibres were richly distributed around acini of the submandibular gland and rare around acini of the sublingual gland.

    In plain wordsIn rats, nerve fibres holding the body's own VIP were common around submandibular gland cells but rare around sublingual gland cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP-containing nerve fibre distribution
    Study

    ratn: not reported in source

    Rat submandibular and sublingual salivary glands
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    VIP-containing nerve fibres were richly distributed around acini in the submandibular gland but were rare around acini of the sublingual gland.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 06AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In rat salivary glands, VIP-receptor mRNA was strongly expressed in acinar cells of the submandibular gland but not in the sublingual gland.

    In plain wordsIn rats, the receptor that VIP acts on was found in submandibular gland cells but not in the sublingual gland.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP-receptor mRNA expression in salivary glands
    Study

    ratn: not reported in source

    Rat submandibular and sublingual salivary glands
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    Vasoactive intestinal polypeptide (VIP)-receptor mRNA was strongly expressed in the acinar cells in the submandibular gland but not in the sublingual gland.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 12:41 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.